Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.68 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RAD52 | P43351 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259497 | 0.92 | AURKA (0.85) | AURKACHEK1MAP2K1KMT2AMEN1 | |
| SCHEMBL10063645 | 0.89 | AURKA (0.80) | AURKACHEK1MAP2K1KMT2AMEN1 | |
| SCHEMBL756639 | 0.89 | AURKA (1.00) | AURKACHEK1MAP2K1KMT2AMEN1 | |
| SCHEMBL735986 | 0.89 | AURKA (1.00) | AURKACHEK1MAP2K1KMT2AMEN1 | |
| SCHEMBL756819 | 0.88 | AURKA (0.78) | AURKACHEK1MAP2K1 | |
| SCHEMBL757420 | 0.86 | AURKA (0.76) | AURKACHEK1MAP2K1KMT2AMEN1 | |
| SCHEMBL757678 | 0.86 | AURKA (0.76) | AURKACHEK1KMT2AMEN1RAD52 | |
| SCHEMBL757332 | 0.85 | AURKA (1.00) | AURKACHEK1MAP2K1 | |
| SCHEMBL763359 | 0.84 | AURKA (0.84) | AURKACHEK1MAP2K1 | |
| SCHEMBL735226 | 0.83 | AURKA (1.00) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| CN-102014627-B | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (CN) | 2014-10-29 | — | — | CN | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| CN-102014627-A | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NAT HEALTH RESEARCH INSTITUTES | 2011-04-13 | — | — | CN | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | AURKA 2/4885CHEK1 45/4885MAP2K1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.